血栓弹力图在2型糖尿病合并冠心病患者中的应用

发布时间：2018-06-17 14:34

本文选题：血栓弹力图 + 型糖尿病　；参考：《中国现代药物应用》2017年08期

【摘要】：目的探索血栓弹力图在2型糖尿病合并冠心病患者中的临床应用效果。方法 197例冠心病患者,按照是否合并2型糖尿病分为糖尿病组(64例)和非糖尿病组(133例)。入院后行常规检查及血栓弹力图检测,分析血栓弹力图各指标在两组间的差异。结果糖尿病组患者血栓弹力图主要参数反应时间(R)、凝固时间(K)、血凝块溶解百分比(EPL)、30 min血凝块幅度减少速率(Ly30)低于非糖尿病组,凝固角(Angle角)、血小板最大聚集率(MA)高于非糖尿病组,差异有统计学意义(P0.05)。糖尿病组患者低密度脂蛋白、超敏C反应蛋白(CRP)、空腹血糖、糖化血红蛋白、血小板计数、纤维蛋白原低于非糖尿病组,差异有统计学意义(P0.05)。糖尿病组二磷酸腺苷(ADP)抑制率为(57.10±27.25)%血小板纤维蛋白凝块强度(MAADP)为(29.78±15.97)mm低于非糖尿病组的(64.53±29.24)%、(34.52±14.71)mm,差异有统计学意义(P0.05)。两组花生四烯酸(AA)抑制率比较差异无统计学意义(P0.05)。结论冠心病合并2型糖尿病患者存在血液高凝状态,有血栓栓塞风险。冠心病合并2型糖尿病患者ADP抑制率低,预防心血管事件需加强抗血小板治疗。
[Abstract]:Objective to explore the clinical effect of thromboelastography in type 2 diabetes mellitus with coronary heart disease. Methods 197 patients with coronary heart disease were divided into diabetic group (n = 64) and non-diabetic group (n = 133). After admission, routine examination and thromboelastography were performed to analyze the difference of thromboelastogram indexes between the two groups. Results the main parameters of thromboelastography in diabetic group were as follows: reaction time, coagulation time, percentage of hemagglutination and the reduction rate of hemagglutination amplitude in 30 min were lower than those in non-diabetic group. The maximum platelet aggregation rate (MAA) in angle group was higher than that in non diabetic group (P 0.05). Low density lipoprotein (LDL), hypersensitive C-reactive protein (HDR), fasting blood glucose, glycosylated hemoglobin, platelet count and fibrinogen were significantly lower in the diabetic group than in the non-diabetic group (P 0.05). The inhibition rate of adenosine diphosphate (ADP) in diabetic group was 57.10 卤27.25 渭 g / L platelet fibrin clot strength (MAADP) was 29.78 卤15.97)mm, which was significantly lower than that in non-diabetic group (64.53 卤29.24 卤34.52 卤14.71 mm), and the difference was statistically significant (P 0.05). There was no significant difference in the inhibition rate of AA between the two groups (P 0.05). Conclusion patients with coronary heart disease and type 2 diabetes have hypercoagulable state and risk of thromboembolism. The inhibition rate of ADP in patients with coronary heart disease complicated with type 2 diabetes is low, so it is necessary to strengthen antiplatelet therapy to prevent cardiovascular events.
【作者单位】：重庆医科大学附属第一医院老年病科;
【基金】：国家临床重点专科建设项目(项目编号:国卫办医函[2013]544号)
【分类号】：R541.4;R587.1

【相似文献】